Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation

30 Dec 2014

Abstract excerpt

// Jiang-Jiang Qin 1,* , Wei Wang 1,2,* , Sukesh Voruganti 1 , Hui Wang 3 , Wei-Dong Zhang 4 and Ruiwen Zhang 1,2 1 Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA 2 Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA 3 Institute for Nutritional Sciences, Shanghai Institutes for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25739118
DOI: 10.18632/oncotarget.3098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validationPMID 25739118Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapASemantic proximity Read ↗

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicineSemantic proximity Read ↗

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapySemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Small Molecule Inhibitors of the p53-MDM2Semantic proximity Read ↗

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer DrugsSemantic proximity Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

Recent Advances in Validating MDM2 as a Cancer TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.